Webb28 mars 2024 · SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage … Webb28 mars 2024 · Satsuma Pharmaceuticals, Inc. filed its 10-K on Mar 28, 2024 for the period ending Dec 31, 2024. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion ...
Satsuma Pharmaceuticals, Inc. meldet Ergebnis für das vierte …
Webb31 dec. 2024 · Satsuma Pharmaceuticals is a development-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of … Webb5 mars 2024 · Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is an investigational drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self … husqvarna 320ib blower parts
Satsuma Pharmaceuticals, Inc. Wirtschaftsprüfer äußert Zweifel …
Webb14 nov. 2024 · Satsuma Pharmaceuticals ( STSA) just announced that its migraine drug failed in a late-stage study. The company seems to have effectively given up on the drug … Webb2 feb. 2024 · Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s … WebbNews for Satsuma Pharmaceuticals Inc Stock (STSA) Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors. GlobeNewsWire • … mary l fitzmaurice johnstown pa